A silicon nanopore membrane blood filter enabling anticoagulant free continuous renal replacement therapy for acute kidney injury

硅纳米孔膜血液过滤器可实现无抗凝剂的连续肾脏替代治疗急性肾损伤

• 批准号: 10546997
• 负责人: Charles Blaha
• 金额: $ 102万
• 依托单位: SILICON KIDNEY, LLC
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-19 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10546997
• 关键词: Acute Renal Failure with Renal Papillary Necrosis; Albumins; Animal Model; Anticoagulants; Anticoagulation; Area; Blood; Blood flow; Citrates; Clinical; Clinical Research; Clinical Trials; Coagulation Process; Complex; Critical Illness; Devices; Dose; Fiber; Film; Future; Hemodialysis; Hemolysis; Hemorrhage; Heparin; Hour; Implant; In Vitro; Intensive Care Units; International; Kidney; Legal patent; Length; Liquid substance; Marketing; Mechanics; Membrane; Notification; Patient Admission; Patient-Focused Outcomes; Patients; Permeability; Phase; Polymers; Preparation; Renal Replacement Therapy; Risk; Risk Reduction; Sepsis; Silicon; Small Business Innovation Research Grant; Sterilization; Surface; Surveys; System; Techniques; Technology; Testing; Thinness; Toxin; Urea; Uremia; Validation; Work; biomaterial compatibility; blood filter; commercialization; cost; design; hemocompatibility; hemodynamics; heparin-induced thrombocytopenia; hypoperfusion; improved; nanopore; porcine model; pre-clinical; prototype; research clinical testing

Project Summary Acute Kidney Injury (AKI) commonly occurs in critically ill patients in the ICU. Patients with severe AKI often require continuous renal replacement therapy (CRRT) because it enables hemodynamic stability and better volume control. Anticoagulation therapy is frequently used to keep the CRRT circuit (especially the blood filter) from clotting as many critically ill patients are prothrombotic, and/or when CRRT is commonly performed for multiple days. However, both systemic heparin and regional citrate anticoagulation therapy are associated with higher costs, increased circuit complexity, and complications. Consequently, we propose to develop an anticoagulant-free blood filter (the HemoCartridge) based on the ultra-high-flux and blood compatible silicon nanopore membrane (SNM) technology for extended extracorporeal applications. The HemoCartridge will operate clot free with little to no anticoagulation for the length of a CRRT session to eliminate the costs, complexity, and complications of administering anticoagulation therapy, reduce blood loss, reduce the cost of CRRT due to filter clotting and replacement, and reduce the risk of not delivering an adequate dialytic dose to the critically ill AKI patient. In this SBIR Phase II proposal, we will develop a clinical-scale HemoCartridge and then assess uremic toxin clearance and hemocompatibility on the bench top and in the anephric porcine model.

项目总结